Blackstone Inc’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-52,343
| Closed | -$2.04K | – | 193 |
|
|
2024
Q3 | $2.04K | Hold |
52,343
| – | – | ﹤0.01% | 160 |
|
|
2024
Q2 | $15.2K | Hold |
52,343
| – | – | ﹤0.01% | 173 |
|
|
2024
Q1 | $753K | Hold |
52,343
| – | – | ﹤0.01% | 148 |
|
|
2023
Q4 | $612K | Hold |
52,343
| – | – | ﹤0.01% | 128 |
|
|
2023
Q3 | $785K | Hold |
52,343
| – | – | ﹤0.01% | 124 |
|
|
2023
Q2 | $1.09M | Hold |
52,343
| – | – | ﹤0.01% | 122 |
|
|
2023
Q1 | $462K | Hold |
52,343
| – | – | ﹤0.01% | 140 |
|
|
2022
Q4 | $560K | Hold |
52,343
| – | – | ﹤0.01% | 124 |
|
|
2022
Q3 | $749K | Hold |
52,343
| – | – | ﹤0.01% | 139 |
|
|
2022
Q2 | $1.86M | Hold |
52,343
| – | – | 0.01% | 125 |
|
|
2022
Q1 | $5.25M | Hold |
52,343
| – | – | 0.01% | 132 |
|
|
2021
Q4 | $7.8M | Hold |
52,343
| – | – | 0.02% | 154 |
|
|
2021
Q3 | $18.4M | Buy |
+52,343
| New | +$16.9M | 0.04% | 108 |
|
|
2021
Q2 | – | Sell |
-12,000
| Closed | -$2.92M | – | 667 |
|
|
2021
Q1 | $2.92M | Buy |
+12,000
| New | +$2.95M | 0.01% | 292 |
|
Blackstone Inc's EFTR Position: Q4 2024 in Review
Blackstone Inc sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q4 2024, closing a stake of 52,343 shares — an estimated $2.04K sold.
Blackstone Inc first reported a position in EFTR in Q1 2021 and held it in 14 quarters. The position peaked at $18.4M in Q3 2021. 0 funds tracked by Wall St. Rank hold EFTR as of Q4 2024.
- Blackstone Inc reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Blackstone Inc sold 52,343 eFFECTOR Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $2.04K.
- Blackstone Inc first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2021 and held it in 14 quarters.
- Blackstone Inc's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $18.4M in Q3 2021.
- 0 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q4 2024.
Based on Blackstone Inc's 13F filing for Q4 2024, filed 14 Feb 2025.